1. Hicks AM, Riedlinger G, Willingham MC, et al. Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proc Natl Acad Sci U S A. 2006 May 16;103(20):7753-8.
2. Available at: http://www.newscientist.com/article/mg19526224.800-cancerresistant-people-lend-out-their-killer-cells.html. Accessed January 18, 2010.
3. Benoy IH, Elst H, Philips M, et al. Prognostic significance of disseminated tumor cells as detected by quantitative real-time reverse-transcriptase polymerase chain reaction in patients with breast cancer. Clin Breast Cancer. 2006 Jun;7(2):146-52.
4. Burnett AK, Watkins R, Maharaj D, et al. Transplantation of unpurged autologous bone marrow in acute myeloid leukemia in first remission. Lancet. 1984 Nov 10; 324(8411):1068-70.
5. Carey PJ, Proctor SJ, Taylor P, et al. Autologous bone marrow transplantation for high-grade lymphoid malignancy using melphalan/irradiation conditioning without marrow purging or cryopreservation. Blood. 1991 Apr 1;77(7):1593-98.
6. Reece DE, Bredeson C, Perez WS, et al. Autologous stem cell transplantation in multiple myeloma patients < 60 versus >60 years of age. Bone Marrow Transplant. 2003 Dec;32(12):1135-43.
7. Bashey A, Perez WS, Zhang MJ, et al.Comparison of twin and autologous transplants for multiple myeloma. Biol Blood Marrow Transplant.2008 Oct;14(10):1118-24.
8. Lazarus HM, Carreras J, Boudreau C, et al. Influence of age and histology on outcome in adult non-hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center for International Blood & Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant. 2008 Dec;14(12):1323-33.
9. Passweg JR, Walker I, Sobocinski KA, et al. Validation and extension of the EBMT risk score for patients with chronic myeloid leukemia (CML) receiving allogeneic hematopoietic stem cell transplants. Br J Hematol. 2004 Jun; 125(5):613-20.
10. Baker KS, Loberiza FR, Yu H, et al. Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem cell transplantation in the United States. J Clin Oncol. 2005 Oct 1;23(28):7032-42.
11. Hari P, Carreras J, Zhang MJ, et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant. 2008 Feb;14(2):236-45.
12. Baker KS, Davies SM, Majhail NS, et al. Race and socioeconomic status influence outcomes of unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009 Dec;15(12):1543-54.
13. Crump M, Smith AM, Brandwein J, et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin’s disease: importance of disease status at transplant. J Clin Oncol. 1993 Apr;11(4):704-11.
14. Freedman AS, Gribben JG, Neuberg D, et al. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood. 1996 Oct 1;88(7):2780-6.
15. Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood. 2009 Oct 8;114(15):3139-46.
16. Ladetto M, Pagliano G, Ferrero S, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol. 2010 Apr 20;28(12):2077-84.
17. Protheroe AS, Pickard C, Johnson PW, et al. Persistence of Clonal T-cell Expansions following High-Dose Chemotherapy and Autologous Peripheral Blood Progenitor Cell Rescue. Br J Haematol. 2000 Dec;111(3):766-73.
18. Nieto Y, Shpall EJ, McNiece IK. Prognostic analysis of the early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor cell transplant. Clin Cancer Res. 2004 Aug 1;10(15):5076–86.
19. Porrata LF, Litzow MR, Tefferi A. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia. 2002 Jul;16(7):1311–8.
20. Porrata LF, Inwards DJ, Micallef IN, et al. Early lymphocyte recovery post autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin’s lymphoma. Br J Haematol. 2008 Jun;117(3):629–33.
21. Gordan LN, Sugrue MW, Lynch JW, et al. Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin’s and non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2003 Jun; 31(11):1009–13.
22. Porrata LF, Gertz MA, Inwards DJ, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin’s lymphoma. Blood. 2001 Aug 1;98:579–85.
23. Williams MD, Braun LA, Cooper LM, et al. Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care. Crit Care. 2004 Oct;8(5):R 291-8.
24. Maharaj D, Byrd S, Gouvea J. Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) in the totally outpatient setting for poor risk patients with chemosensitive malignancies. Blood. 1996;86:10 (Suppl 1): 401a.